Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Berzosertib

            Therapeutic Area: Infections and Infectious Diseases Product Name: M6620

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: UCLA Jonsson Comprehensive Cancer Center

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 24, 2021

            Details:

            Berzosertib, which is licensed by Merck KGaA, Darmstadt, Germany, is being investigated in separate early- and mid-stage clinical trials in combination with chemotherapy as a possible treatment for small-cell lung cancer, ovarian cancer and other types of tumors.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Adrecizumab

            Therapeutic Area: Infections and Infectious Diseases Product Name: HAM8101

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 24, 2020

            Details:

            Treatment with Adrecizumab showed an encouraging outcome in this limited data set, seven out of eight patients survived the observation period. Adrecizumab targets Adrenomedullin to restore endothelial barrier function and impaired vascular integrity.